Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Discover New Method to Treat Cancer

20.03.2003


Research at Oxford University’s Institute of Molecular Medicine has identified a novel therapeutic regimen for the treatment of cancer that provides significant advantages over the existing methods of cancer treatment.



There are already a number of regimens available for treatment of cancer, including chemotherapy, which is commonly used to treat a number of different types of cancer. In most cases chemotherapeutic agents are given at the maximum tolerated dose (MTD), but at such doses the treatments can only be given in short courses and often have unacceptable side effects. In recent years, the use of immunotherapy for tumours has also increased, but tumour cells have been shown to evade immunotherapy by mutating to avoid presentation of the specific tumour epitope to the immune system. It has previously been suggested that a combination of immunotherapy and chemotherapy may prove effective as a treatment. However, this has not proved ideal since conventional chemotherapy suppresses the immune system, thereby reducing the effectiveness of the immunotherapy.

Researchers in Oxford have now devised a novel therapeutic regimen that combines the advantages of both chemotherapy and immunotherapy whilst reducing the disadvantages of each. It has been shown that chemotherapeutic agents can have a beneficial effect at doses lower than the MTD (such a dosing regimen has become known as metronomic dosing). Metronomic dosing, whilst not being as aggressive as the MTD regimen, has fewer side effects and can be used for longer periods without a break. The researchers have identified a metronomic regimen that does not cause the severe immunosuppression of standard chemotherapy and so opens the possibility of combining immunotherapy and chemotherapy. Furthermore, they have shown that such a combination therapy is more effective at inhibiting tumour growth than either chemotherapy (at MTD or as a metronomic dose), or immunotherapy alone or than immunotherapy in combination with chemotherapy at MTD.


Isis Innovation, Oxford University’s technology transfer company, has filed a patent on this exciting Oxford discovery. Companies interested in product developments arising from this work are invited to contact Isis to discuss how they could utilise this technology.

Jennifer Johnson | alfa
Further information:
http://www.isis-innovation.com/licensing/1194.html

More articles from Health and Medicine:

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht FAU researchers demonstrate that an oxygen sensor in the body reduces inflammation
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>